Trials / Completed
CompletedNCT05040802
Effectiveness of Adacel Vaccination in Pregnancy at Preventing Pertussis in Infants < 2 Months of Age in the United States
Effectiveness of Adacel Vaccination in Pregnancy at Preventing Pertussis in Infants < 2 Months of Age in the United States (US)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 462 (actual)
- Sponsor
- Sanofi Pasteur, a Sanofi Company · Industry
- Sex
- All
- Age
- 2 Days – 2 Months
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine the effectiveness of Adacel against pertussis disease in infants \< 2 months when administered during pregnancy following the current Advisory Committee on Immunization Practices (ACIP) recommendations, i.e., from 27 to 36 weeks of gestation, and 14 days or more before delivery.
Detailed description
The original study included cases recorded from 01 January 2011 through 31 December 2014, based on retrospective case-control methodology.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Not applicable / dataset analysis | Not applicable / dataset analysis |
Timeline
- Start date
- 2021-06-02
- Primary completion
- 2021-10-04
- Completion
- 2021-10-04
- First posted
- 2021-09-10
- Last updated
- 2023-04-13
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT05040802. Inclusion in this directory is not an endorsement.